Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of CancerSteven Langston, Xiaofeng Yang, Anya Lublinsky et al.|Journal of Medicinal Chemistry|2021Cited by 205
A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical modelsEric S. Lightcap, Dennis Huszar, Serge Y. Fuchs et al.|Science Translational Medicine|2021Cited by 139